MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
2024年6月5日紐約時報快訊——MiNK Therapeutics公司(NASDAQ:INKT)是一家致力於發現、研發和商業化同種異體、現成的固有NK T(iNKT)細胞療法以治療癌症和其他免疫介導性疾病的臨床生物製藥公司, 宣佈其股東年度大會將於2024年6月12日美國東部時間上午9:30開始,且將僅以虛擬格式進行。參會者的註冊將在美國東部時間上午9:15開始。
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.
股東們要參加年度股東大會,需要訪問www.virtualshareholdermeeting.com/INKT2024,並輸入其代理材料中找到的16位控制號。來賓也可以以聽講爲模式訪問會議,不需要控制號。
Webcast Information:
網絡直播信息:
Date: Wednesday, June 12, 2024
日期:2024年6月12日星期三
Time: 9:30 a.m. ET
時間:美國東部時間上午9:30
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at www.virtualshareholdermeeting.com/INKT2024.
About MiNK Therapeutics
MiNK Therapeutics簡介
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MiNK Therapeutics是一家臨床生物製藥公司,致力於發現、研發和商業化同種異體不變自然殺傷T細胞(iNKT)療法,以治療癌症和其他免疫介導性疾病。MiNK正在推進一系列原生和下一代工程iNKT計劃,平台旨在爲現成送貨提供可擴展和可重複生產的工具。公司總部位於紐約市。欲了解更多信息,請訪問https://minktherapeutics.com/或關注@MiNK_iNKT。可能對投資者重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Investor Contact
投資者聯繫方式
917-362-1370
917-362-1370
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
來源:MiNK治療